Sibylle Loibl talks through the PENELOPE-B trial of palbociclib plus endocrine therapy for hormone receptor-positive breast cancer patients who did not respond to neoadjuvant chemotherapy and discusses what is known so far about CDK4/6 inhibitors in the adjuvant setting.
Joseph Sparano explains the advantages of combining the 21-gene recurrence score with tumor characteristics and patient age when determining the benefits of adjuvant chemotherapy for a woman with node-negative breast cancer.
Masataka Sawaki explains why adjuvant trastuzumab monotherapy may be considered for older patients with HER2-positive invasive breast cancer despite not meeting noninferiority criteria compared with trastuzumab plus chemotherapy.
This site is intended for healthcare professionals in France, Germany, Italy, Japan and the United Kingdom only.
The selection of ASCO content on this site was made by the ASCO Publication and Education teams. Springer Healthcare selected the experts for interview. All content is made available solely for educational and informational purposes and personal use only.